On September 30, Acpharis CSO, Sandor Vajda, will jointly present a short course with Adrian Whitty, Associate Professor of Chemistry at Boston University, on “Understanding and Targeting Protein-Protein Interactions.” Acpharis’s exclusive license to PIPER for protein-protein docking and expertise in applying computational solvent mapping to protein-protein interaction targets give it the tools to probe these interfaces and understand the underlying biophysical mechanisms that allow the development of methods to address this novel class of targets.

At two conferences today, GTC Bio's Drug Discovery and Medicinal Chemistry in San Diego and CHI's Structure-Based Drug Discovery in Cambridge, Acpahris's CEO and CSO described the use of computational solvent mapping to guide the development of fragment hits into leads.

Acpharis has granted a license to Schrödinger for the use of the PIPER protein-protein docking in their new biologics program BioLuminate. PIPER is a state of the art protein-protein docking program licensed to Acpharis by Boston University.